Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 605-611

  Barginear, M F ^a   Jaremko, M ^a,b   Peter, I ^a   Yu, C ^a   Kasai, Y ^a   Kemeny, M ^c   Raptis, G ^a   Desnick, R J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ATHENA DIAGNOSTICS INC   (United States)

^c Queens Cancer Center of Queens Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ANTIESTROGENIC ACTIVITY SCORE; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIAPHORESIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG METABOLISM; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; VAGINAL DRYNESS;

ADULT; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 80052971654     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.153     Document Type: Article

References (39)

1. Jemal, A. et al. Cancer statistics, 2008. CA. Cancer J. Clin. 58, 71-96 (2008).
2. Early Breast Cancer Trialists' Collaborative Group (EBCTC G). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
3. Early Breast Cancer Trialists' Collaborative Group (EBCTC G). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
4. Jordan, V.C. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat. 2, 123-138 (1982). (Pubitemid 13233530)
5. Lim, Y.C., Desta, Z., Flockhart, D.A. & Skaar, T.C. Endoxifen (4-hydroxy-Ndesmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 55, 471-478 (2005). (Pubitemid 40568978)
6. Lim, Y.C. et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OHtamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J. Pharmacol. Exp. Ther. 318, 503-512 (2006).
7. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N. & Spelsberg, T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 69, 1722-1727 (2009).
8. Jaremko, M., Kasai, Y., Barginear, M.F., Raptis, G., Desnick, R.J. & Yu, C. Tamoxifen metabolite isomer separation and quantification by liquid chromatographytandem mass spectrometry. Anal. Chem. 82, 10186-10193 (2010).
9. Dahmane, E. et al. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878, 3402-3414 (2010).
10. Goetz, M.P. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007). (Pubitemid 47555336)
11. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
12. Goetz, M.P., Kamal, A. & Ames, M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther. 83, 160-166 (2008).
13. Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
14. Wegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B. & Wingren, S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9, R7 (2007).
15. Borges, S. et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006). (Pubitemid 43946844)
16. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
17. Kiyotani, K. et al. Significant effect of polymorphisms in CYP2D6 and ABCC 2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28, 1287-1293 (2010).
18. Flockhart, D.A. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicinehttp://medicine.iupui.edu/clinpharm/ ddis/table.aspx (2007).
19. Rae, J.M.et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. 33rd Annual San Antonio Breast Cancer Symposium; Abstract S1-7 (2010).
20. Leyland-Jones, B.et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. 33rd Annual San Antonio Breast Cancer Symposium; Abstract S1-8 (2010).
21. Hawse, J.et al. The impact of estrogen receptor-beta on the actions of endoxifen in breast cancer cells. Cancer Res. 69 (24, suppl.), Abstract 405 (2009).
22. Madlensky, L. et al. Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes. Clin. Pharmacol. Ther. 89, 718-725 (2011).
23. Dezentjé, V.O. et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol. 28, 2423-2429 (2010).
24. Howell, A. et al.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
25. C oates, A.S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007). (Pubitemid 350002953)
26. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). (Pubitemid 350232249)
27. Bijl, M.J. et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 118, 125-130 (2009).
28. Wegman, P. et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7, R284-R290 (2005).
29. Ramon Y., Cajal, T.et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 119, 33-38 (2010).
30. Lim, H.S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.J. & Ro, J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25, 3837-3845 (2007). (Pubitemid 47477258)
31. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075 (2004). (Pubitemid 39108928)
32. Brauch, H., Mürdter, T.E., Eichelbaum, M. & Schwab, M. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55, 1770-1782 (2009).
33. Lazarus, P., Blevins-Primeau, A.S., Zheng, Y. & Sun, D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann. NY Acad. Sci. 1155, 99-111 (2009).
34. Furr, B.J. & Jordan, V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25, 127-205 (1984). (Pubitemid 14015738)
35. Scott, S.A., Edelmann, L., Kornreich, R., Erazo, M. & Desnick, R.J. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 8, 721-730 (2007). (Pubitemid 47288973)
36. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997). (Pubitemid 27058401)
37. Gardiner, S.J. & Begg, E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58, 521-590 (2006). (Pubitemid 44403684)
38. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J. & Leeder, J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
39. Gjerde, J., Kisanga, E.R., Hauglid, M., Holm, P.I., Mellgren, G. & Lien, E.A. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1082, 6-14 (2005). (Pubitemid 40848583)